SUMM.L

Summit Therapeutics Plc
Completion of $50 million Fundraising and Directorate Change
24th December 2019, 08:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Completion of <money>$50 million</money> Fundraising and Directorate Change

Summit Therapeutics plc
(“Summit Therapeutics” or the “Company”)

Completion of $50 million Subscription and Placing and Directorate Changes

Oxford, UK, and Cambridge, MA, US, 24 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription and placing of new ordinary shares and warrants (the “Fundraising”) to raise approximately $50 million, which was approved by shareholders at the Company’s general meeting held on 23 December 2019, has completed. The subscription shares, comprising 166,157,050 new ordinary shares, and placing shares, comprising 9,221,400 new ordinary shares, were admitted to trading on AIM effective at 8:00 a.m. GMT on 24 December 2019.

Completion of the Fundraising means that the proposed restructuring of the Company’s board of directors (the “Board”) is now effective.  The restructured Board now comprises Mr Robert W. Duggan, Mr Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov as non-executive directors, and Mr Glyn Edwards as Chairman in addition to his role as the Company’s Chief Executive Officer. Dr Frank Armstrong, Mr Leopoldo Zambeletti and Mr David Wurzer stepped down from the Board effective today.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

For more information, please contact:

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti  
   
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / George Tzimas, Corporate Finance
Tom Salvesen, Corporate Broking		  
   
Bryan Garnier & Co Limited (Joint Broker)Tel:+44 (0)20 7332 2500
Phil Walker / Dominic Wilson  
   
MSL Group (US)Tel:+1 781 684 6552
Erin Anthoine summit@mslgroup.com
   
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart /
Sukaina Virji / Lindsey Neville		 summit@consilium-comms.com

-END-

]]>

TwitterFacebookLinkedIn